AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
Retrieved on:
Monday, September 20, 2021
Survival analysis, Tyrosine kinase inhibitor, Person, Science, Vall, AMF, Death, Veterinary medicine, Neuromuscular Disorders, B cell, Cell, Disorder, Macrophage, Riluzole, Inflammation, Euronext Paris, Peripheral nervous system, Annual general meeting, Central nervous system, Alness United F.C., Lists of diseases, Medicine, Disease, Survival, Muscle, Peaceful transition of power, Motor neuron, Observation, Degenerative disease, Marketing, Company, Amyotrophic lateral sclerosis, Motor neuron disease, PKI, Microglia, Immunity, Euronext, Hospital, News, Patient, Immunotherapy, AB, Prevalence, ALS, Research, Vaccine, Pharmaceutical industry
This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).
Key Points:
- This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).
- We first suspected that masitinib may generate improved survival in certain subgroups through observation of patients enrolled in study AB10015 at the Vall d'Hebron Hospital's ALS Unit [2].
- 2020;21(1-2):5-14. doi:10.1080/21678421.2019.1632346
[2] Gamez J. Vall dHebron participates in an international study to validate masitinib for amyotrophic lateral sclerosis treatment. - In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy.